Asset Details
Do you wish to reserve the book?
ALS-008176 for Respiratory Syncytial Virus Infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ALS-008176 for Respiratory Syncytial Virus Infection
Do you wish to request the book?
ALS-008176 for Respiratory Syncytial Virus Infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ALS-008176 for Respiratory Syncytial Virus Infection
2016
Overview
To the Editor:
DeVincenzo and colleagues (Nov. 19 issue)
1
report antiviral activity of ALS-008176 in healthy adults infected with the respiratory syncytial virus (RSV). Their study showed faster viral clearance and less severe symptoms in the groups that received ALS-008176 than in the placebo group, and these outcomes were further enhanced by the addition of a loading dose.
The authors acknowledge that their study was limited by the participants’ preexisting immune memory, which may have contributed to clearance of RSV infection. It should be noted that in the intention-to-treat (ITT) infected population, RSV antibody titers before inoculation, as measured on . . .
Publisher
Massachusetts Medical Society
